Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.40 |
| ▸ | LMNA | P02545 | 2/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.40 |
| ▸ | HTT | P42858 | 1/20 | 0.40 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.38 |
| ▸ | TSHR | P16473 | 2/20 | 0.37 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.37 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.36 |
| ▸ | CFTR | P13569 | 1/20 | 0.36 |
| ▸ | MEN1 | O00255 | 1/20 | 0.36 |
| ▸ | CA1 | P00915 | 1/20 | 0.36 |
| ▸ | CA2 | P00918 | 1/20 | 0.36 |
| ▸ | CA5A | P35218 | 1/20 | 0.36 |
| ▸ | CA9 | Q16790 | 1/20 | 0.36 |
| ▸ | DRD2 | P14416 | 1/20 | 0.36 |
| ▸ | GAA | P10253 | 1/20 | 0.36 |
| ▸ | MAPT | P10636 | 1/20 | 0.36 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.36 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23565659 | 0.88 | KMT2A (0.39) | ALDH1A1LMNAKMT2AHTTSLC6A3 | |
| SCHEMBL14312138 | 0.86 | MAPK1 (0.38) | ALDH1A1LMNAKMT2AHTTTSHR | |
| SCHEMBL8106855 | 0.83 | KMT2A (0.52) | ALDH1A1LMNAKMT2AHTTSLC6A3 | |
| SCHEMBL31184912 | 0.83 | DRD2 (0.38) | ALDH1A1LMNAKMT2AHTTSLC6A3 | |
| SCHEMBL29549457 | 0.82 | KMT2A (0.43) | ALDH1A1LMNAKMT2AHTTSLC6A3 | |
| SCHEMBL29613534 | 0.82 | TSHR (0.44) | ALDH1A1LMNAKMT2AHTTSLC6A3 | |
| SCHEMBL2246779 | 0.82 | KMT2A (0.43) | ALDH1A1LMNAKMT2AHTTSLC6A3 | |
| SCHEMBL24510725 | 0.82 | TSHR (0.44) | ALDH1A1LMNAKMT2AHTTSLC6A3 | |
| SCHEMBL27432088 | 0.82 | KMT2A (0.46) | ALDH1A1LMNAKMT2AHTTSLC6A3 | |
| SCHEMBL29240001 | 0.81 | KMT2A (0.39) | ALDH1A1LMNAKMT2AHTTSLC6A3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 279 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12029738-B2 | Antiproliferative compounds and methods of use thereof | CELGENE CORPORATION (US) | 2024-07-09 | — | — | US | claimed |
| US-20220280505-A1 | ANTIPROLIFERATIVE COMPOUNDS AND METHODS OF USE THEREOF | CELGENE CORPORATION | 2022-09-08 | — | — | US | claimed |
| EP-4731611-A1 | TARGETED DEGRADERS OF HIV-1 NEF FOR THE TREATMENT OF HIV DISEASE | UNIVERSITY OF PITTSBURGH - OF THE COMMONWEALTH SYSTEM OF HIGHER EDUCATION (US) | 2026-04-29 | — | — | EP | disclosed |
| EP-3886904-B1 | IRAK DEGRADERS AND USES THEREOF | KYMERA THERAPEUTICS INC (US) | 2026-04-22 | — | — | EP | disclosed |
| EP-4725553-A2 | SOLID FORMS COMPRISING (S)-4-(4-(4-(((2-(2,6-DIOXOPIPERIDIN-3-YL)-1-OXOISOINDOLIN-4-YL)OXY)METHYL) BENZYL)PIPERAZIN-1-YL)-3-FLUOROBENZONITRILE AND SALTS THEREOF, AND COMPOSITIONS COMPRISING AND METHODS OF USING THE SAME | Celgene Corporation (US) | 2026-04-15 | — | — | EP | disclosed |
| EP-4467143-B1 | METHOD FOR PREPARING 4-(4-(4-(((2-(2,6-DIOXOPIPERIDIN-3-YL)-L-OXOISOINDOLIN-4-YL)OXY)METHYL)BENZYL)PIPERAZIN-L-YL)-3-FLUOROBENZONITRILE | CELGENE CORP (US) | 2026-03-11 | — | — | EP | disclosed |
| US-20260007679-A1 | METHODS OF TREATING CANCER USING 3-(4-((4-(MORPHOLINOMETHYL)BENZYL)OXY)-1-OXOISOINDOLIN-2-YL)PIPERIDINE-2,6-DIONE | CELGENE CORP (US) | 2026-01-08 | — | — | US | disclosed |
| US-12510533-B2 | Methods for treating multiple myeloma and the use of companion biomarkers for 4-(4-(4-(((2-(2,6-dioxopiperidin-3-yl)-1-oxoisoindolin-4-yl)oxy)methyl)benzyl)piperazin-1-yl)-3-fluorobenzonitrile | CELGENE CORPORATION (US) | 2025-12-30 | — | — | US | disclosed |
| EP-3908582-B1 | SOLID FORMS COMPRISING (S)-4-(4-(4-(((2-(2,6-DIOXOPIPERIDIN-3-YL)-1-OXOISOINDOLIN-4-YL)OXY)METHYL) BENZYL)PIPERAZIN-1-YL)-3-FLUOROBENZONITRILE AND SALTS THEREOF, AND COMPOSITIONS COMPRISING AND METHODS OF USING THE SAME | CELGENE CORP (US) | 2025-11-12 | — | — | EP | disclosed |
| US-20250288573-A1 | DIMERIC IMMUNO-MODULATORY COMPOUNDS AGAINST CEREBLON-BASED MECHANISMS | H. LEE MOFFITT CANCER CENTER AND RESEARCH INSTITUTE, INC. | 2025-09-18 | — | — | US | disclosed |
| US-12391672-B2 | Solid forms comprising (S)-4-(4-(4-(((2-(2,6-dioxopiperidin-3-yl)-1-oxoisoindolin-4-yl)oxy)methyl)benzyl)piperazin-1-yl)-3-fluorobenzonitrile and salts thereof, and compositions comprising and methods of using the same | CELGENE CORPORATION (US) | 2025-08-19 | — | — | US | disclosed |
| US-20140045844-A1 | TREATMENT OF IMMUNE-RELATED AND INFLAMMATORY DISEASES | CELGENE CORPORATION (US) | 2014-02-13 | — | — | US | disclosed |
| US-20130324518-A1 | ARYLMETHOXY ISOINDOLINE DERIVATIVES AND COMPOSITIONS COMPRISING AND METHODS OF USING THE SAME | CELGENE CORPORATION (US) | 2013-12-05 | — | — | US | disclosed |
| US-8518972-B2 | Arylmethoxy isoindoline derivatives and compositions comprising and methods of using the same | CELGENE CORPORATION (US) | 2013-08-27 | — | — | US | disclosed |
| US-8518972-B2 | Arylmethoxy isoindoline derivatives and compositions comprising and methods of using the same | CELGENE CORPORATION (US) | 2013-08-27 | — | — | US | disclosed |
| US-8518972-B2 | Arylmethoxy isoindoline derivatives and compositions comprising and methods of using the same | CELGENE CORPORATION (US) | 2013-08-27 | — | — | US | disclosed |
| EP-2536706-A1 | ARYLMETHOXY ISOINDOLINE DERIVATIVES AND COMPOSITIONS COMPRISING AND METHODS OF USING THE SAME | Celgene Corporation (US) | 2012-12-26 | — | — | EP | disclosed |
| WO-2011100380-A1 | ARYLMETHOXY ISOINDOLINE DERIVATIVES AND COMPOSITIONS COMPRISING AND METHODS OF USING THE SAME | CELGENE CORPORATION (US) | 2011-08-18 | — | — | WO | disclosed |
| US-20110196150-A1 | Arylmethoxy Isoindoline Derivatives and Compositions Comprising and Methods of Using the Same | CELGENE CORPORATION | 2011-08-11 | — | — | US | disclosed |
| US-20110196150-A1 | Arylmethoxy Isoindoline Derivatives and Compositions Comprising and Methods of Using the Same | CELGENE CORPORATION | 2011-08-11 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (9 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130324518-A1 | ARYLMETHOXY ISOINDOLINE DERIVATIVES AND COMPOSITIONS COMPRISING AND METHODS OF USING THE SAME | CYP3A7, CYP3A4, CYP3A43 | ALDH1A1 1096/4885LMNA 2785/4885KMT2A 4025/4885 |
| US-12029738-B2 | Antiproliferative compounds and methods of use thereof | MCL1, NPM1, NFATC1 | ALDH1A1 2344/4885LMNA 308/4885KMT2A 356/4885 |
| US-20260007679-A1 | METHODS OF TREATING CANCER USING 3-(4-((4-(MORPHOLINOMETHYL)BENZYL)OXY)-1-OXOISOINDOLIN-2-YL)PIPERIDINE-2,6-DIONE | MALT1, BCL6, BCL9 | ALDH1A1 4317/4885LMNA 1633/4885KMT2A 1736/4885 |
| US-20250288573-A1 | DIMERIC IMMUNO-MODULATORY COMPOUNDS AGAINST CEREBLON-BASED MECHANISMS | CRBN, CD4, CDR2 | ALDH1A1 4425/4885LMNA 4549/4885KMT2A 3266/4885 |
| US-20110196150-A1 | Arylmethoxy Isoindoline Derivatives and Compositions Comprising and Methods of Using the Same | CYP3A7, CYP3A4, CYP3A43 | ALDH1A1 1096/4885LMNA 2785/4885KMT2A 4025/4885 |
| US-12510533-B2 | Methods for treating multiple myeloma and the use of companion biomarkers for 4-(4-(4-(((2-(2,6-dioxopiperidin-3-yl)-1-oxoisoindolin-4-yl)oxy)methyl)benzyl)piperazin-1-yl)-3-fluorobenzonitrile | IKZF1, IKZF3, IKZF2 | ALDH1A1 3404/4885LMNA 1860/4885KMT2A 324/4885 |
| US-20220280505-A1 | ANTIPROLIFERATIVE COMPOUNDS AND METHODS OF USE THEREOF | MCL1, NPM1, NFATC1 | ALDH1A1 2344/4885LMNA 308/4885KMT2A 356/4885 |
| US-20140045844-A1 | TREATMENT OF IMMUNE-RELATED AND INFLAMMATORY DISEASES | MYD88, CD14, NFATC1 | ALDH1A1 2726/4885LMNA 2618/4885KMT2A 1451/4885 |
| US-12391672-B2 | Solid forms comprising (S)-4-(4-(4-(((2-(2,6-dioxopiperidin-3-yl)-1-oxoisoindolin-4-yl)oxy)methyl)benzyl)piperazin-1-yl)-3-fluorobenzonitrile and salts thereof, and compositions comprising and methods of using the same | FLNB, H4C1; H4C2; H4C3; H4C4; H4C5; H4C6; H4C8; H4C9; H4C11; H4C12; H4C13; H4C14; H4C15; H4C16, SF3B2 | ALDH1A1 2425/4885LMNA 380/4885KMT2A 1035/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.